AstraZeneca stock: Technical strength and robust EPS drive 1.33% advance

Traders Union
All News
Financial News
AstraZeneca up 1.33% at GBX 14,225

Highlights

AstraZeneca reported total revenue of $43.2 billion for the first nine months of 2025, up 11%, with core EPS rising 15% to $7.04, beating market expectations.
The company is advancing its late-stage drug pipeline, investing in obesity and autoimmune CAR-T therapies, and expanding US manufacturing capacity.
AstraZeneca's Vietnamese subsidiary underscores its sustainability focus, while recent increases in insider share sales signal evolving internal sentiment.

Earnings beat and drug pipeline strengthen investor conviction

AstraZeneca delivered robust financial results for the first nine months of 2025, with total revenue up 11% at $43.2 billion and core EPS rising 15% to $7.04, exceeding market expectations. Strategic developments include continued investment in its late-stage drug pipeline, initiatives in obesity and autoimmune CAR-T therapies, expanded US manufacturing, and a focus on sustainable business through its Vietnamese subsidiary. Recent increases in insider share sales also reflect evolving internal sentiment.

Overbought signals compete with persistent upside momentum

The technical setup for AZN remains bullish with prices significantly above all major moving averages. The dynamic resistance is at the Ichimoku Kijun level of GBX 14,376.18, while strong support is seen at the MA-50. Momentum indicators such as MACD and ADX confirm ongoing buyer strength. However, RSI, Stochastic RSI, and CCI show overbought conditions, warning of possible short-term overheating. The Bull/Bear Power indicator and Awesome Oscillator continue to signal strong demand and persistent positive momentum, but rising volatility and emerging divergence on oscillators suggest caution for new positions.

Further price gains likely as volatility brackets upside risk

For the next five trading days, AZN is likely to trade within a typical volatility band of GBX 13,950 to GBX 14,450. There is a strong (over 80%) chance of further price increases, supported by robust technical signals. In a bullish scenario, a break above GBX 14,376.18 could lead to further gains toward GBX 14,450, while a move below GBX 13,950 may trigger a correction toward the MA-50; however, a downside shift remains unlikely unless technical momentum fades.

Anton Kharitonov, expert at Traders Union, notes AstraZeneca’s technical momentum remains strong, but short-term risk is rising. He sees robust fundamentals and positive sentiment, yet highlights that overbought signals and increased insider sales justify caution. Strong support at MA-50 and dynamic resistance near GBX 14,376.18 define tactical boundaries. "With momentum stretched and volatility rising, I will wait for a clear pullback before considering new long positions."

Last time, analysts noted that AstraZeneca PLC was trading above its key moving averages with strong bullish momentum confirmed by positive MACD and ADX signals, although overbought oscillators such as RSI and Stochastic RSI suggested the stock was stretched in the short term. Price action was expected to consolidate between established support and resistance levels, with buyers maintaining upward pressure and a high probability of further gains if a breakout occurred above technical resistance.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.